- Home
- AMBC vs KROS Comparison
AMBC vs KROS Comparison
Compare AMBC & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBC
- KROS
- Stock Information
- Founded
- AMBC 1971
- KROS 2015
- Country
- AMBC United States
- KROS United States
- Employees
- AMBC N/A
- KROS N/A
- Industry
- AMBC Property-Casualty Insurers
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- AMBC Finance
- KROS Health Care
- Exchange
- AMBC Nasdaq
- KROS Nasdaq
- Market Cap
- AMBC 411.3M
- KROS 558.9M
- IPO Year
- AMBC 1991
- KROS 2020
- Fundamental
- Price
- AMBC $7.62
- KROS $14.17
- Analyst Decision
- AMBC Strong Buy
- KROS Buy
- Analyst Count
- AMBC 1
- KROS 13
- Target Price
- AMBC $15.00
- KROS $20.63
- AVG Volume (30 Days)
- AMBC 953.5K
- KROS 601.6K
- Earning Date
- AMBC 08-04-2025
- KROS 08-06-2025
- Dividend Yield
- AMBC N/A
- KROS N/A
- EPS Growth
- AMBC N/A
- KROS N/A
- EPS
- AMBC N/A
- KROS 0.11
- Revenue
- AMBC $253,912,000.00
- KROS $214,713,000.00
- Revenue This Year
- AMBC N/A
- KROS $5,006.76
- Revenue Next Year
- AMBC $17.41
- KROS N/A
- P/E Ratio
- AMBC N/A
- KROS $127.57
- Revenue Growth
- AMBC 125.08
- KROS 91657.70
- 52 Week Low
- AMBC $5.99
- KROS $9.12
- 52 Week High
- AMBC $13.64
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- AMBC 60.91
- KROS 59.31
- Support Level
- AMBC $6.97
- KROS $13.26
- Resistance Level
- AMBC $8.07
- KROS $13.77
- Average True Range (ATR)
- AMBC 0.29
- KROS 0.37
- MACD
- AMBC 0.11
- KROS 0.05
- Stochastic Oscillator
- AMBC 71.88
- KROS 92.54
About AMBC Ambac Financial Group Inc.
Ambac Financial Group Inc is a financial services holding company. It operates in two principal businesses segments: Insurance Distribution and Specialty Property & Casualty Insurance. Insurance Distribution segment includes Managing General Agents, Underwriters and other appointed and delegated underwriting businesses (collectively MGAs or MGA/Us), an insurance broker, and other distribution and underwriting businesses. Specialty Property & Casualty Insurance includes five carriers (collectively, Everspan). Key revenue is generated from Insurance Distribution.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.